Marfan syndrome (MFS) is a heritable connective tissue disorder usually caused by a mutation in the fibrillin 1 (FBN1) gene. Typical characteristics of MFS that have been described are e.g. dolichostenomelia, ectopia lentis and aortic root dilatation. However, there is great clinical variability in the expression of the syndrome's manifestations, both between and within families. Here we discuss the clinical variability of MFS by describing a large four-generation Dutch family with MFS.
introduCtion
Marfan syndrome (MFS) is a heritable connective tissue disorder primarily involving the ocular, skeletal and the cardiovascular system. 1 The diagnosis is made according to the Ghent nosology (Table 1) . 1 Typical characteristics of MFS are dolichostenomelia (thin body habitus and long extremities), ectopia lentis (lens (sub-)luxation), pectus carinatum/excavatum, and aortic root dilatation. 1, 2 There is, however, extensive variability in the phenotype of MFS patients, both between and within affected families. [3] [4] [5] The prevalence of MFS is relatively low, approximately 1:5,000, but considering the great clinical heterogeneity less typical patients may well remain undiagnosed. 6 The syndrome is usually caused by a mutation in the fibrillin-1 (FBN1) gene on chromosome 15. In about 25% of the patients this is the result of a de novo mutation, in other cases the mutation is inherited in an autosomal dominant way. 7, 8 In rare cases, MFS is caused by a mutation in the table 1. Diagnostic criteria for Marfan syndrome according to Ghent nosology. 1 At least two major criteria from two different organ systems + involvement of a third organ system is required for a diagnosis of Marfan syndrome. 
Central nervous system
-lumbal sacral dural ectasia none * 2 major or 1 major + 2 minor criteria required for the skeletal system to be involved transforming growth factor beta (TGF-β) receptor 1 or 2 genes. [9] [10] [11] Although MFS is often the result of a transmitted mutation, large families with MFS spanning multiple generations with a single founder mutation have rarely been reported. In this article series on recurrent and founder mutations we present a large, four-generation Dutch family and another unrelated patient with a single recurrent FBN1 missense mutation that has not been reported before. To our knowledge this is one of the largest families described in the literature. On the basis of this family and the unrelated patient we discuss the clinical variability of the syndrome.
PAtients And Methods
Clinical data were collected from the Marfan outpatients' clinics at the University Medical Center Groningen, Radboud University Nijmegen Medical Center, Leiden University Medical Center and Academic Medical Center Amsterdam.
Mutation analysis
Genomic DNA was extracted from peripheral blood leukocytes and mutational analysis of the 
resuLts

Clinical
Four index patients were evaluated for MFS in four different centers. After diagnosing MFS, DNA analysis revealed an identical FBN1 mutation (see below). Subsequent genealogical investigation revealed that three of the four index patients could be traced back to one ancestral couple. In Figure 1 the pedigree of the family is presented and in table 2 the phenotypic characteristics of the patients according to the Ghent nosology are displayed. Nineteen patients all carrying the same FBN1 mutation (see below) could be linked to each other ( Figure 1 ). One index patient was shown to harbour the identical FBN1 mutation but he could not be linked to the pedigree. Most patients expressed important cardiovascular manifestations: eight patients had aortic root dilatation, two other patients had an acute type A aortic dissection, and seven had a mitral valve prolapse. In some patients cardiac manifestations were not present at the initial screening, but did develop over time. For example patient IV-7 showed no cardiac features at the age of ten, but eight years later he had an aortic root dilatation and a mitral valve prolapse. Skeletal symptoms varied widely 
Genetic analysis
A missense mutation in exon 63 (c.7916A>G) leading to a change of amino acid tyrosine into cysteine at position 2639 (p.Y2639C) was identified in all the tested family members (table 2) . This amino acid concerns a highly conserved residue in calcium-binding epidermal growth factor (EGF)-like domain 42. The new cysteine residue is predicted to disturb disulphide bonding, which is essential for the stability of the EGF-like domains of fibrillin and will affect protein stability. The mutation was absent in an ethnically-matched healthy control population (n=1,000 chromosomes) and has not been described as a cause of MFS before.
One index patient (final patient in table 2) could not be linked to the large family, but carries the same FBN1 mutation. Both his parents were examined for skeletal, cardiological and ocular symptoms but did not show any symptoms of MFS. His mother tested negative for the FBN1 mutation. His father was not tested. An additional silent DNA variant was detected in exon 43 in this patient. This variant, c.5343G>A:[p.V1781V] was not found in the mother and hence is located on the paternal allele that contains the mutation in exon 63.
haplotype analysis
Haplotype analysis revealed an identical haplotype for affected individuals from the large family around the FBN1 gene for seven markers located within a 2.3 Mb region on chromosome 15. This haplotype was absent in the unrelated patient who carried the same mutation (data not shown).
disCussion
MFS is diagnosed according to the Ghent nosology (see table 1 for the diagnostic criteria) and is usually caused by a mutation in the FBN1 gene. 1, 7 Fibrillin-1 is an extracellular matrix protein regulating TGF-β activity, which is a cytokine that plays an important role in cell proliferation and differentiation, apoptosis and extracellular matrix formation. 13, 14 Increased TGF-β signalling plays an important role in the pathogenesis of MFS, causing deleterious effects on, for example the aortic wall, the mitral valve, and pulmonary tissue. 13, 15, 16 More than 1,000 different mutations, spread throughout the entire gene, have been identified in the FBN1 gene. 17, 18 The types of mutations are diverse, although missense mutations are the most prevalent, in particular a missense mutation affecting a cysteine residue, leading to a disruption of the tertiary structure of fibrillin. 19 Most mutations are unique for a certain MFS family, and only approximately 10% of mutations are recurrent in different families. 20 In about 25% of individual Marfan patients, the syndrome is caused by a de novo mutation in the FBN1 gene. In other cases, MFS is the result of an autosomal dominantly transmitted mutation. 8 Here we have both situations: a recurrent missense mutation which spread through four generations in one family and an identical mutation which is believed to be de novo in a single MFS patient. Because the different index patients were ascertained in different centres and were not aware of each other and the fact that this is a large four generation family, we suggest that this mutation can be considered a founder mutation. Large MFS families spanning multiple generations are rare and the MFS family presented here constitutes an exception as few such large families have been described in the literature. 21 The FBN1 mutation described here, was found in one unrelated individual, who had a neutral variant on the mutant allele that was not present in the large family. Haplotype analysis of repeat markers in and around the FBN1 gene showed no common haplotype. Consequently this mutation does not appear to be a founder mutation in this particular index patient.
The potentially aggressive nature of MFS could explain the rare occurrence of large MFS families.
Patients with severe (cardiovascular) complications early in life might not produce offspring, making multiple-generation families less likely to occur.
MFS is known for its clinical variability, both between families and within families, as also evident in the family we describe. fibrillin-1 is predominantly derived from the normal allele (non-mutated allele). 5 In addition, Van Dijk et al. described two families with MFS, in which certain individuals had two FBN1 mutations, and suggested that the additional mutations might have a modifying role as a cause of intrafamilial variability. 22 Giusti et al. found a relationship between severity of cardiovascular manifestations and elevated homocysteine levels. 4 It should further be kept in mind that many genes are involved in the complicated process of extracellular matrix formation, many parts of which have yet to be discovered. These genes are likely to play an important role in modifying the phenotypic expression of MFS.
ConCLusion
We have described a unique, large four-generation Marfan syndrome family, in which 19 individuals have a single missense founder mutation in the FBN1 gene (c.7916A>G). We also found the same mutation in one other, unrelated individual, proving that this mutation can also be recurrent. The mutation carriers showed extensive clinical variability in symptoms and signs of MFS and not all mutation carriers fulfilled diagnostic criteria for MFS, even at advanced ages. The variability in the phenotypic expression makes a careful clinical and genetic evaluation of suspected cases crucial.
Mutation carriers should undergo regular follow-up with regards to the cardiovascular system as symptoms may develop over time.
